Minireview: More than just a hammer: Ligand "bias" and pharmaceutical discovery

Molecular Endocrinology

Volumn 28, Issue 3, 2014, Pages 281-294

  Luttrell, Louis M ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; RETINA S ANTIGEN;

ALLOSTERISM; CELL ASSAY; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG PROGRAM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; NONHUMAN; PARTIAL AGONISM; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SPATIOTEMPORAL ANALYSIS;

ALLOSTERIC REGULATION; ANIMALS; DRUG DISCOVERY; HUMANS; LIGANDS; PHARMACOLOGY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84896703861     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2013-1314     Document Type: Review

References (168)

1. Ellis C. The state of GPCR research in 2004. Nat Rev Drug Discov. 2004; 3: 577-626.
2. Karlin A. On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine. J Theor Biol. 1967; 16: 306-320.
3. Thron CD. On the analysis of pharmacological experiments in terms of an allosteric receptor model. Mol Pharmacol. 1973; 9: 1-9.
4. Black JW, Leff P. Operational models of pharmacological agonist. Proc R Soc Lond [Biol]. 1983; 220: 141-162.
5. Black JW, Leff P, Shankley NP. An operational model of pharmacological agonism: The effect of E/[A] curve shape on agonist dissociation constant estimation. Br J Pharmacol. 1985; 84: 561-571.
6. Samama P, Cotecchia S, Costa T, Lefkowitz RJ. A mutation-induced activated state of the β 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem. 1993; 268: 4625-4636.
7. Weiss JM, Morgan PH, Lutz MW, Kenakin TP. The cubic ternary complex receptor-occupancy model. III. Resurrecting efficacy. J Theor Biol. 1996; 181: 381-397.
8. Maslow AH. The Psychology of Science. New York, NY: Harper Row; 1996: 15.
9. Kenakin T. Pharmacological proteus? Trends Pharmacol Sci. 1995; 16: 256-258.
10. Wilson S, Bergsma DJ, Chambers JK, et al. Orphan G-proteincoupled receptors: the next generation of drug targets? Br J Pharmacol. 1998; 125: 1387-1392.
11. Howard AD, McAllister G, Feighner SD, et al. Orphan G-proteincoupled receptors and natural ligand discovery. Trends Pharmacol Sci. 2001; 22: 132-140.
12. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab. 2001; 12: 118-122.
13. Xu YL, Jackson VR, Civelli O. Orphan G protein-coupled receptors and obesity. Eur J Pharmacol. 2004; 500: 243-253.
14. Galandrin S, Bouvier M. Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogenactivated protein kinase reveals the pluridimensionality of efficacy. Mol Pharmacol. 2006; 70: 1575-1584.
15. Offermanns S, Wieland T, Homann D, et al. Transfected muscarinic acetylcholine receptors selectively couple to Gi-type G proteins and Gq/11. Mol Pharmacol. 1994; 45: 890-898.
16. Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci USA. 1996; 93: 116-120.
17. Jin LQ, Wang HY, Friedman E. Stimulated D (1) dopamine receptors couple to multiple Gα proteins in different brain regions. J Neurochem. 2001; 78: 981-990.
18. Luttrell LM, Lefkowitz RJ. The role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002; 115: 455-465.
19. Luttrell LM, Gesty-Palmer D. Beyond desensitization: Physiological relevance of arrestin-dependent signaling. [published correction appears in Pharmacol Rev. 2010; 62: 564]. Pharmacol Rev. 2010; 62305-62330.
20. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharm Rev. 2001; 53: 1-24.
21. Lefkowitz RJ. G protein-coupled receptor kinases. Cell. 1993; 74: 409-412.
22. Goodman OB Jr., Krupnick JG, Santini F, et al. β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor. Nature. 1996; 383: 447-450.
23. Laporte SA, Oakley RH, Zhang J, et al. The β2-adrenergic receptor/ β-arrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci USA. 1999; 96: 3712-3717.
24. Luttrell LM, Ferguson SS, Daaka Y, et al. β-Arrestin-dependent formation ofβ2 adrenergic receptor-Src protein kinase complexes. Science. 1999; 283: 655-661.
25. DeFea KA, Vaughn ZD, O'Bryan EM, Nishijima D, Déry O, Bunnett NW. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a β-arrestin-dependent scaffolding complex. Proc Natl Acad Sci USA. 2000; 97: 11086-11091.
26. Barlic J, Andrews JD, Kelvin AA, et al. Regulation of tyrosine kinase activation and granule release through β-arrestin by CXCRI. Nat Immunol. 2000; 1: 227-233.
27. McDonald PH, Chow CW, Miller WE, et al. β-Arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science. 2000; 290: 1574-1577.
28. DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000; 148: 1267-1281.
29. Luttrell LM, Roudabush FL, Choy EW, et al. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc Natl Acad Sci USA. 2001; 98: 2449-2454.
30. Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated β2-adrenergic receptor and β-arrestin. Science. 2001; 294: 1307-1313.
31. Perry SJ, Baillie GS, Kohout TA, et al. Targeting of cyclic AMP degradation to β 2-adrenergic receptors by β-arrestins. Science. 2002; 298: 834-836.
32. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ. Targeting of diacylglycerol degradation toM1muscarinic receptors by β-arrestins. Science. 2007; 315: 663-666.
33. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IκBα. Proc Natl Acad Sci USA. 2004; 101: 8603-8607.
34. Bhattacharya M, Anborgh PH, Babwah AV, et al. β-Arrestins regulate a Ral-GDS Ral effector pathway that mediates cytoskeletal reorganization. Nat Cell Biol. 2002; 4: 547-555.
35. Zoudilova M, Kumar P, Ge L, Wang P, Bokoch GM, DeFea KA. β-Arrestin-dependent regulation of the cofilin pathway downstream of protease-activated receptor-2. J Biol Chem. 2007; 282: 20634-20646.
36. Beaulieu JM, Sotnikova TD, Yao WD, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA. 2004; 101: 5099-5104.
37. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/β-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005; 122: 261-273.
38. Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of β-arrestin-and G protein-biased agonists. Trends Mol Med. 2011; 17: 126-139.
39. Kenakin T. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci. 1995; 16: 232-238.
40. Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev. 2002; 54: 323-374.
41. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat Rev Drug Discov. 2005; 4: 919-927.
42. Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci. 2007; 28: 382-389.
43. Kenakin TP. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol Sci. 2009; 30: 460-469.
44. Kenakin T, Miller LJ. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev. 2010; 62: 265-304.
45. Luttrell LM, Kenakin TP. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol Biol. 2011; 756: 3-35.
46. Spengler D, Waeber C, Pantaloni C, et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature. 1993; 365: 170-175.
47. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol. 1998; 54: 94-104.
48. Sagan S, Chassaing G, Pradier L, Lavielle S. Tachykinin peptides affect differently the second messenger pathways after binding to CHO-expressed human NK-1 receptors. J Pharmacol Exp Ther. 1996; 276: 1039-1048.
49. Takasu H, Gardella TJ, Luck MD, Potts JT Jr., Bringhurst FR. Amino-terminal modifications of human parathyroid hormone (PTH) selectively alter phospholipase C signaling via the type 1 PTH receptor: Implications for design of signal-specific PTH ligands. Biochemistry. 1999; 38: 13453-13460.
50. Gray JA, Roth BL. Paradoxical trafficking and regulation of 5-HT (2A) receptors by agonists and antagonists. Brain Res Bull. 2001; 56: 441-451.
51. Holloway AC, Qian H, Pipolo L, et al. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol Pharmacol. 2002; 61: 768-777.
52. Sneddon WB, Magyar CE, Willick GE, et al. Ligand-selective dissociation of activation and internalization of the parathyroid hormone (PTH) receptor: conditional efficacy of PTH peptide fragments. Endocrinology. 2004; 145: 2815-2823.
53. Seifert R, Gether U, Wenzel-Seifert K, Kobilka BK. Effects of guanine, inosine, and xanthine nucleotides on β (2)-adrenergic receptor/ G (s) interactions: evidence for multiple receptor conformations. Mol Pharmacol. 1999; 56: 348-358.
54. Perez DM, Hwa J, Gaivin R, Mathur M, Brown F, Graham RM. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol Pharmacol. 1996; 49: 112-122.
55. Barroso S, Richard F, Nicolas-Ethève D, Kitabgi P, Labbé-Jullié C. Constitutive activation of the neurotensin receptor 1 by mutation of Phe (358) in helix seven. Br J Pharmacol. 2002; 135: 997-1002.
56. Swaminath G, Xiang Y, Lee TW, Steenhuis J, Parnot C, Kobilka BK. Sequential binding of agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem. 2004; 279: 686-691.
57. Swaminath G, Deupi X, Lee TW, et al. Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem. 2005; 280: 22165-22171.
58. Zürn A, Zabel U, Vilardaga JP, Schindelin H, Lohse MJ, Hoffmann C. Fluorescence resonance energy transfer analysis of β2aadrenergic receptor activation reveals distinct agonist-specific conformational changes. Mol Pharmacol. 2009; 75: 534-541.
59. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship? Mol Pharmacol. 2007; 72: 1393-1401.
60. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. Functional dissocation of μ-opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron. 1999; 23: 737-746.
61. Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL. [D-Arg1, D-Phe5, D-Trp7, 9, Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem. 1998; 273: 3097-3104.
62. Kudlacek O, Waldoer M, Kassack MU, et al. Biased inhibition by a suramin analogue of A1-adenosine receptor/G protein coupling in fused receptor/G protein tandems: the A1 adenosine receptor is predominantly coupled to Goα in human brain. Naunyn Schmiedeberg's Arch Pharmacol. 2002; 365: 8-16.
63. Manning DR. Measures of efficacy using G proteins as endpoints: differential engagement of G proteins through single receptors. Mol Pharmacol. 2002; 62: 451-452.
64. Gurwitz D, Haring R, Heldman E, Fraser CM, Manor D, Fisher A. Discrete activation of transduction pathways associated with acetylcholine M1 receptor by several muscarinic ligands. Eur J Pharmacol. 1994; 267: 21-31.
65. Kohout TA, Nicholas SL, Perry SJ, Reinhart G, Junger S, Struthers RS. Differential desensitization, receptor phosphorylation, β-arrestin recruitment, and ERK1/2 activation by the two endogenous ligands for the CC chemokine receptor 7. J Biol Chem. 2004; 279: 23214-23222.
66. Wei H, Ahn S, Shenoy SK, et al. Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA. 2003; 100: 10782-10787.
67. Azzi M, Charest PG, Angers S, et al. β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA. 2003; 100: 11406-11411.
68. Gesty-Palmer D, Chen M, Reiter E, et al. Distinct β-arrestin-and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006; 281: 10856-10864.
69. Altenbach C, Kusnetzow AK, Ernst OP, Hofmann KP, Hubbell WL. High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation. Proc Natl Acad Sci USA. 2008; 105: 7439-7444.
70. Choe HW, Kim YJ, Park JH, et al. Crystal structure of metarhodopsin II. Nature. 2011; 471: 651-655.
71. Nygaard R, Zou Y, Dror RO, et al. The dynamic process of β (2)-adrenergic receptor activation. Cell. 2013; 152: 532-542.
72. Rasmussen SG, DeVree BT, Zou Y, et al. Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature. 2011; 477: 549-555.
73. Liu JJ, Horst R, Katritch V, Stevens RC, Wüthrich K. Biased signaling pathways in β2-adrenergic receptor characterized by 19FNMR. Science. 2012; 335: 1106-1110.
74. Zocher M, Fung JJ, Kobilka BK, Müller DJ. Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor. Structure. 2012; 20: 1391-1402.
75. Coulon V, Audet M, Homburger V, et al. Subcellular imaging of dynamic protein interactions by bioluminescence resonance energy transfer. Biophys J. 2008; 94: 1001-1009.
76. Lohse MJ, Nuber S, Hoffmann C. Fluorescence/bioluminescence resonance energy transfer techniques to study G-protein-coupled receptor activation and signaling. Pharmacol Rev. 2012; 64: 299-336.
77. Saulière A, Bellot M, Paris H, et al. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nat Chem Biol. 2012; 8: 622-630.
78. Gesty-Palmer D, Luttrell LM. Heptahelical terpsichory. Who calls the tune? J Recept Signal Transduct Res. 2008; 28: 39-58.
79. Christensen GL, Kelstrup CD, Lyngsø C, et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics. 2010; 9: 1540-1553.
80. 8]angiotensin II regulates a robust G proteinindependent signaling network. J Biol Chem. 2011; 286: 19880-19891.
81. Rajagopal K, Whalen EJ, Violin JD, et al. β-Arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc Natl Acad Sci USA. 2006; 103: 16284-16289.
82. Aplin M, Christensen GL, Schneider M, et al. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin Pharmacol Toxicol. 2007; 100: 296-301.
83. Gesty-Palmer D, Yuan L, Martin B, et al. β-Arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo. Mol Endocrinol. 2013; 27: 296-314.
84. Luttrell LM. 'Location, location, location': activation and targeting of MAP kinases by G protein-coupled receptors. J Mol Endocrinol. 2003; 30: 117-126.
85. Stork PJ. ERK signaling: duration, duration, duration. Cell Cycle. 2002; 1: 315-317.
86. Dean T, Vilardaga JP, Potts JT Jr., Gardella TJ. Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor. Mol Endocrinol. 2008; 22: 156-166.
87. Ferrandon S, Feinstein TN, Castro M, et al. Sustained cyclic AMP production by parathyroid hormone receptor endocytosis. Nat Chem Biol. 2009; 5: 734-742.
88. Vilardaga JP, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell Mol Life Sci. 2011; 68: 1-13.
89. Shimizu N, Dean T, Tsang JC, Khatri A, Potts JT Jr., Gardella TJ. Novel parathyroid hormone (PTH) antagonists that bind to the juxtamembrane portion of the PTH/PTH-related protein receptor. J Biol Chem. 2005; 280: 1797-1807.
90. Okazaki M, Ferrandon S, Vilardaga JP, Bouxsein ML, Potts JT Jr., Gardella TJ. Prolonged signaling at the parathyroid hormone receptor by peptide ligands targeted to a specific receptor conformation. Proc Natl Acad Sci USA. 2008; 105: 16525-16530.
91. Zimmerman B, Beautrait A, Aguila B, et al. Differential β-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci Signal. 2012; 5: ra33.
92. Tobin AB, Butcher AJ, Kong KC. Location, location, location... site-specific GPCR phosphorylation offers a mechanism for celltype-specific signalling. Trends Pharmacol Sci. 2008; 29: 413-420.
93. Wisler JW, DeWire SM, Whalen EJ, et al. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci USA. 2007; 104: 16657-16662.
94. Qin L, Raggatt LJ, Partridge NC. Parathyroid hormone: A doubleedged sword for bone metabolism. Trends Endocrinol Metab. 2004; 15: 60-65.
95. Mohan S, Kutilek S, Zhang C, et al. Comparison of bone formation responses to parathyroid hormone (1-34), (1-31), and (2-34) in mice. Bone. 2000; 27: 471-478.
96. Gesty-Palmer D, Flannery P, Yuan L, Spurney R, Lefkowitz RJ, Luttrell LM. A β-arrestin biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation. Sci Transl Med. 2009; 1: 1ra1.
97. Violin JD, DeWire SM, Yamashita D, et al. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010; 335: 572-579.
98. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett JC Jr. Cardiorenal actions of TRV120027, a novel ß-arrestinbiased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail. 2011; 4: 770-778.
99. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC Jr. TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. Circ Heart Fail. 2012; 5: 627-634.
100. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT. Enhanced morphine analgesia in mice lackingβ-arrestin 2. Science. 1999; 286: 2495-2498.
101. Bohn LM, Lefkowitz RJ, Caron MG. Differential mechanisms of morphine antinociceptive tolerance revealed in β-arrestin-2 knock-out mice. J Neurosci. 2002; 22: 10494-10500.
102. DeWire SM, Yamashita DS, Rominger DH, et al. A G proteinbiased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013; 344: 708-717.
103. Walters RW, Shukla AK, Kovacs JJ, et al. β-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest. 2009; 119: 1312-1321.
104. Semple G, Skinner PJ, Gharbaoui T, et al. 3-(1H-tetrazol-5-yl)-1, 4, 5, 6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem. 2008; 51: 5101-5108.
105. Beaulieu JM, Marion S, Rodriguiz RM, et al. A β-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008; 132: 125-136.
106. Masri B, Salahpour A, Didriksen M, et al. Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA. 2008; 105: 13656-13661.
107. Wang L, Martin B, Brenneman R, Luttrell LM, Maudsley S. Allosteric modulators of G protein-coupled receptors: future therapeutics for complex physiological disorders. J Pharmacol Exp Ther. 2009; 331: 340-348.
108. Luttrell LM. Arrestin pathways as drug targets. Prog Mol Biol Transl Sci. 2013; 118: 469-497.
109. Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136: 3632-3638.
110. Deng ZL, Sharff KA, Tang N, et al. Regulation of osteogenic differentiation during skeletal development. Front Biosci. 2008; 13; 2001-2021.
111. Lian JB, Stein GS, Javed A, et al. Networks and hubs for the transcriptional control of osteoblastogenesis. Rev Endocr Metab Disord. 2006; 7: 1-16.
112. Lymperopoulos A, Rengo G, Zincarelli C, Kim J, Soltys S, Koch WJ. An adrenalβ-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc Natl Acad Sci USA. 2009; 106: 5825-5830.
113. Kim J, Zhang L, Peppel K, et al. β-Arrestins regulate atherosclerosis and neointimal hyperplasia by controlling smooth muscle cell proliferation and migration. Circ Res. 2008; 103: 70-79.
114. Miura S, Zhang J, Matsuo Y, Saku K, Karnik SS. Activation of extracellular signal-activated kinase by angiotensin II-induced Gq-independent epidermal growth factor receptor transactivation. Hypertens Res. 2004; 27: 765-770.
115. Kim J, Ahn S, Rajagopal K, Lefkowitz RJ. Independentβ-arrestin2 and Gq/protein kinase C pathways for ERK stimulated by angiotensin type 1A receptors in vascular smooth muscle cells converge on transactivation of the epidermal growth factor receptor. J Biol Chem. 2009; 284: 11953-11962.
116. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ. β-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem. 2009; 284: 8855-8865.
117. Kim IM, Tilley DG, Chen J, et al. β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci USA. 2008; 105: 14555-14560.
118. Cottingham C, Chen Y, Jiao K, Wang Q. The antidepressant desipramine is an arrestin-biased ligand at the α (2A)-adrenergic receptor driving receptor down-regulation in vitro and in vivo. J Biol Chem. 2011; 286: 36063-36075.
119. Ryman-Rasmussen JP, Griffith A, Oloff S, et al. Functional selectivity of dopamine D1 receptor agonists in regulating the fate of internalized receptors. Neuropharmacology. 2007; 52: 562-575.
120. Hartley O, Gaertner H, Wilken J, et al. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA. 2004; 101: 16460-16465.
121. Ahn KH, Mahmoud MM, Shim JY, Kendall DA. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1). J Biol Chem. 2013; 288: 9790-9800.
122. Zhou L, Lovell KM, Frankowski KJ, et al. Development of functionally selective, small molecule agonists at κ opioid receptors. J Biol Chem. 2013; 288: 36703-36716.
123. Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM. Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at μ-opioid receptors in striatal neurons. J Biol Chem. 2013; 288: 22387-22398.
124. Raehal KM, Bohn LM. β-Arrestins: regulatory role and therapeutic potential in opioid and cannabinoid receptor-mediated analgesia. Handb Exp Pharmacol. 2014; 219: 427-443.
125. Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptormediated signaling pathways. Neuropsychopharmacology. 2007; 32: 67-77.
126. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA. 2008; 105: 1079-1084.
127. Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci. 2010; 30: 13513-13524.
128. Jorgensen R, Kubale V, Vrecl M, Schwartz TW, Elling CE. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor β-arrestin recruitment and signaling through Gα (s). J Pharmacol Exp Ther. 2007; 322: 148-154.
129. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM. β-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic β cells. Proc Natl Acad Sci USA. 2008; 105: 6614-6619.
130. Dalle S, Ravier MA, Bertrand G. Emerging roles forβ-arrestin-1 in the control of the pancreatic β-cell function and mass: new therapeutic strategies and consequences for drug screening. Cell Signal. 2011; 23: 522-528.
131. de Roux N, Milgrom E. Inherited disorders of GnRH and gonadotropin receptors. Mol Cell Endocrinol. 2001; 179: 83-87.
132. Duprez L, Parma J, Van Sande J, et al. TSH receptor mutations and thyroid disease. Trends Endocrinol Metab. 1998; 9: 133-140.
133. Barak LS, Oakley RH, Laporte SA, Caron MG. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA. 2001; 98: 93-98.
134. Nichols HL, Saffeddine M, Theriot BS, et al. β-Arrestin-2 mediates the proinflammatory effects of proteinase-activated receptor-2 in the airway. Proc Natl Acad Sci USA. 2012; 109: 16660-16665.
135. Penn RB, Bond RA, Walker JK. GPCRs and Arrestins in Airways: Implications for Asthma. Handb Exp Pharmacol. 2014; 219: 387-403.
136. Ramachandran R, Mihara K, Chung H, et al. Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J Biol Chem. 2011; 286: 24638-24648.
137. Lau C, Lytle C, Straus DS, DeFea KA. Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium. Am J Physiol Cell Physiol. 2011; 300: C113-123.
138. Sobolesky PM, Moussa O. The role of β-arrestins in cancer. Prog Mol Biol Transl Sci. 2013; 118: 395-411.
139. Jiang D, Xie T, Liang J, Noble PW. β-Arrestins in the immune system. Prog Mol Biol Transl Sci. 2013; 118: 359-393.
140. Kenakin TP. Ligand detection in the allosteric world. J Biomol Screen. 2010; 15: 119-130.
141. Kenakin TP. Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol. 2012; 165: 1659-1669.
142. Kenakin T, Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov. 2013; 12: 205-216.
143. Milligan G. High-content assays for ligand regulation of G-protein coupled receptors. Drug Disc Today. 2003; 8: 579-585.
144. Ross DA, Lee S, Reiser V, et al. Multiplexed assays by high-content imaging for assessment of GPCR activity. J Biomol Screen. 2008; 13: 449-455.
145. Ghosh RN, DeBiasio R, Hudson CC, Ramer ER, Cowan CL, Oakley RH. Quantitative cell-based high-content screening for vasopressin receptor agonists using transfluor technology. J Biomol Screen. 2005; 10: 476-484.
146. Hanson BJ, Wetter J, Bercher MR, et al. A homogeneous fluorescent live-cell assay for measuring 7-transmembrane receptor activity and agonist functional selectivity through β-arrestin recruitment. J Biomol Screen. 2009; 14: 798-810.
147. Hamdan FF, Audet M, Garneau P, Pelletier J, Bouvier M. High throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based β-arrestin2 recruitment assay. J Biomol Screen. 2005; 10: 463-475.
148. Zhao X, Jones A, Olson KR, et al. A homogeneous enzyme fragment complementation-based β-arrestin translocation assay for high-throughput screening of G-protein-coupled receptors. J Biomol Screen. 2008; 13: 737-747.
149. Barnea G, Strapps W, Herrada G, et al. The genetic design of signaling cascades to record receptor activation. Proc Natl Acad Sci USA. 2008; 105: 64-69.
150. Henriksen U, Fog J, Loechel F, Praestegaard M. Profiling of multiple signal pathway activities by multiplexing antibody and GFPbased translocation assays. Comb Chem High Throughput Screen. 2008; 11: 537-544.
151. Kenakin T. Quantifying biased β-arrestin signaling. Handb Exp Pharmacol. 2014; 219: 57-83.
152. Fang Y, Ferrie AM, Fontaine NH, Yuen PK. Characteristics of dynamic mass redistribution of epidermal growth factor receptor signaling in living cells measured with label-free optical biosensors. Anal Chem. 2005; 77: 5720-5725.
153. Cunningham BT, Li P, Schultz S, et al. Label free assays on the BIND system. J Biomol Screen. 2004; 9: 481-490.
154. Fang Y, Ferrie AM. Label-free optical biosensor for ligand-directed functional selectivity acting on β2-adrenoceptor in living cells. FEBS Lett. 2008; 582: 558-564.
155. McGuinness R. Impedance-based cellular assay technologies: recent advances, future promise. Curr Opin Pharmacol. 2007; 7: 535-540.
156. Peters MF, Scott CW. Evaluating cellular impedance assays for detection of GPCR pleiotropic signaling and functional selectivity. J Biomol Screen. 2009; 14: 246-255.
157. Congreve M, Langmead C, Marshall FH. The use of GPCR structures in drug design. Adv Pharmacol. 2011; 62: 1-36.
158. Kooistra AJ, Roumen L, Leurs R, de Esch IJ, de Graaf C. From heptahelical bundle to hits from the haystack: structure-based virtual screening for GPCR ligands. Methods Enzymol. 2013; 522: 279-336.
159. Kołaczkowski M, Bucki A, Feder M, Pawłowski M. Ligand-optimized homology models of D1 and D2 dopamine receptors: application for virtual screening. J Chem Inf Model. 2013; 53: 638-648.
160. Lane JR, Chubukov P, Liu W, et al. Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. Mol Pharmacol. 2013; 84: 794-807.
161. Kuang G, Hu G, Sun X, Li W, Liu G, Tang Y. In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists. J Mol Model. 2012; 18: 3831-3845.
162. Renault N, Laurent X, Farce A, et al. Virtual screening of CB (2) receptor agonists from bayesian network and high-throughput docking: structural insights into agonist-modulated GPCR features. Chem Biol Drug Des. 2013; 81: 442-454.
163. Yoshikawa Y, Oishi S, Kubo T, Tanahara N, Fujii N, Furuya T. Optimized method of G-protein-coupled receptor homology modeling: its application to the discovery of novel CXCR7 ligands. J Med Chem. 2013; 56: 4236-4251.
164. Weiss DR, Ahn S, Sassano MF, et al. Conformation guides molecular efficacy in docking screens of activated β-2 adrenergic G protein coupled receptor. ACS Chem Biol. 2013; 8: 1018-1026.
165. Grassi G, Seravalle G, Quarti-Trevano F, Dell'oro R. Sympathetic activation in congestive heart failure: evidence, consequences and therapeutic implications. Curr Vasc Pharmacol. 2009; 7: 137-145.
166. Maudsley S, Patel SA, Park SS, Luttrell LM, Martin B. Functional signaling biases in G protein-coupled receptors: game theory and receptor dynamics. Mini-Rev Med Chem. 2012; 12: 831-840.
167. Nemeth EF, Heaton WH, Miller M, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004; 308: 627-635.
168. Muniz-Medina VM, Jones S, Maglich JM, et al. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol Pharmacol. 2009; 75: 490-501.